Efficacy of Stellate Ganglion Block in Obstructive Sleep Apnea

Obstructive Sleep Apnea Clinical Trial

— OSA  

Official title:

A Randomized Controlled Trial to Explore the Efficacy of Stellate Ganglion Block in Obstructive Sleep Apnea

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06265792
• Other study ID #: 2024-KY-0125
• Status: Not yet recruiting
• Phase: N/A
• Start date: March 1, 2024
• Est. completion date: December 15, 2024

Study information

• Verified date: March 2024
• Source: People's Hospital of Zhengzhou University
• Contact: Zhefeng Wang, Master
• Phone: 19501376864
• Email: zhengzhouzhj[@]qq.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to test the efficacy of stellate ganglion block in Obstructive Sleep Apnea. The main question it aims to answer are:

• Can stellate ganglion block improve Obstructive Sleep Apnea? Patients were randomly divided into two groups, all provided with routine therapy. Based on this, the experimental group was given stellate ganglion block. The video fluoroscopic swallowing study was done to test the swallowing function before and after the study.

Description:

Obstructive Sleep Apnea is of increasingly high prevalence.

The goal of this clinical trial is to test the efficacy of stellate ganglion block in Obstructive Sleep Apnea. The main question it aims to answer are:

• Can stellate ganglion block improve Obstructive Sleep Apnea? Patients were randomly divided into two groups, all provided with routine therapy. Based on this, the experimental group was given stellate ganglion block. The video fluoroscopic swallowing study was done to test the swallowing function before and after the study.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 80
• Est. completion date: December 15, 2024
• Est. primary completion date: December 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients aged over 18 years diagnosed with OSA by polysomnography

• Patients with moderate to severe OSA (AHI > 15 events per hour)

• Patients who have undergone continuous positive airway pressure (CPAP) treatment for at least 3 months but have not achieved satisfactory therapeutic effects

• Patients who voluntarily agree to receive stellate ganglion block (SGB) treatment and sign the informed consent form

Exclusion Criteria:

• Patients with a history of allergy or contraindications to local anesthetics or corticosteroids

• Patients with severe cardiovascular, cerebrovascular, respiratory, hepatic, or renal diseases

• Patients with a history of neck surgery or cervical spine disease

• Patients with psychiatric disorders or other medical conditions that may affect the safety or effectiveness of SGB treatment

• Pregnant or lactating women

• Patients who have participated in other clinical trials within the past 3 months

Related Conditions & MeSH terms

• Apnea
• Obstructive Sleep Apnea
• Sleep Apnea Syndromes
• Sleep Apnea, Obstructive

Intervention

Behavioral:
• routine rehabilitation treatment
All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy

Procedure:
• Stellate ganglion block
The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.

Locations

Country	Name	City	State
Korea, Republic of	Center Rehabilitation Hospital	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Zeng Changhao

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Epworth Sleepiness Scale	This scale measures daytime sleepiness. By scoring the level of sleepiness in different situations, it can help evaluate whether a patient has OSA or other sleep disorders.Scores range from 0-24. Higher scores indicate more severe daytime sleepiness.	day 1 and day 20
Secondary	Apnea-Hypopnea Index	Apnea-Hypopnea Index is a method to evaluate the severity of OSA. It calculates the number of apnea and hypopnea events per hour.	day 1 and day 20